Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance AI Agent Platform

Silo Pharma (NASDAQ:SMPL) announced that its wholly owned subsidiary, QwikAgents, has joined AMD’s AI Developer Program, giving the company access to AI development resources intended to support the expansion of its enterprise and consumer AI agent platform.

Key Investor Takeaways

• Silo Pharma (NASDAQ:SMPL) said QwikAgents has been accepted into the AMD AI Developer Program.
• The program provides access to AMD Developer Cloud credits, AI development tools, training resources, and a global developer ecosystem.
• Management expects the resources to support development, testing, optimization, and deployment of the QwikAgents AI platform.
• QwikAgents is targeting enterprise, developer, small business, and consumer markets with persistent AI agents for workflow automation and productivity.
• The announcement expands Silo Pharma’s technology initiatives beyond its core biopharmaceutical development programs.

Why SMPL Stock Is in Focus

Silo Pharma announced that its QwikAgents subsidiary has joined the AMD AI Developer Program, providing access to cloud infrastructure, development tools, training, and technical resources designed to accelerate AI application development.

According to the company, the program will support the ongoing development of QwikAgents, a platform designed to allow users to deploy AI agents for applications including research, coding, content generation, browser automation, scheduling, and workflow automation.

The company said the platform is being developed with features including persistent memory, dedicated agent infrastructure, smart model routing, encrypted backups, and scalable deployment options for both individual users and enterprise customers.

Management expects participation in the AMD program to assist with hosting, benchmarking, optimization, testing, and potential training of AI workloads as the platform continues to expand.

Why This Matters for Investors

The announcement highlights Silo Pharma’s continued effort to build an AI software business alongside its biopharmaceutical pipeline.

Participation in the AMD AI Developer Program may provide technical resources that help accelerate platform development while reducing some infrastructure barriers during the product’s growth phase. If successful, the initiative could support broader commercialization of QwikAgents across consumer and enterprise markets.

However, the announcement does not include commercial agreements, customer wins, or financial guidance related to the platform. The potential business impact will depend on future product adoption, platform development, and customer growth.

What to Watch Next

Investors will likely monitor:

• New features and commercial milestones for the QwikAgents platform.
• Customer adoption across enterprise, developer, and consumer markets.
• Product performance improvements resulting from participation in the AMD AI Developer Program.
• Future partnerships or commercial agreements related to AI agent deployment.
• Updates on how the AI platform complements Silo Pharma’s broader business strategy.

Silo Pharma stock price